Tag: Bypassing agents

For individuals with hemophilia and inhibitors, the development of antibodies against standard clotting factors makes treatment challenging, necessitating the use of bypassing agents like FEIBA. Knowing **when to give FEIBA** is critical for effective bleeding management, whether for acute episodes or prophylactic care. This medication acts by circumventing the inhibited factor to restore the body's clotting ability.

Feiba, also known as Anti-inhibitor Coagulant Complex, has a history of over 30 years of use in controlling bleeding episodes in hemophilia patients who have developed inhibitors. Specifically, **what is the use of Feiba injection?** It is a crucial therapeutic option for those with hemophilia A or B who have developed antibodies (inhibitors) against their standard clotting factor treatments, making those therapies ineffective. Feiba works by bypassing the inhibited factor to restore the blood clotting process and stop bleeding.